Q1 Earnings Forecast for Septerna Issued By HC Wainwright

Septerna, Inc. (NASDAQ:SEPN) – Investment analysts at HC Wainwright decreased their Q1 2026 EPS estimates for Septerna in a research note issued to investors on Wednesday, March 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.46) per share for the quarter, down from their prior estimate of ($0.25). HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna’s Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.70) EPS, FY2026 earnings at ($2.34) EPS and FY2027 earnings at ($3.13) EPS.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, March 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%. The business had revenue of $24.12 million for the quarter, compared to analyst estimates of $20.44 million.

A number of other analysts have also recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $60.00 price objective on shares of Septerna in a research report on Tuesday. Wells Fargo & Company increased their target price on Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, March 3rd. Truist Financial lifted their price target on shares of Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd. Finally, Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Septerna Trading Down 4.9%

NASDAQ SEPN opened at $25.14 on Friday. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -22.65 and a beta of 3.46. The stock has a 50-day moving average of $26.78 and a 200 day moving average of $23.39. Septerna has a twelve month low of $4.66 and a twelve month high of $32.63.

Institutional Investors Weigh In On Septerna

A number of large investors have recently modified their holdings of SEPN. Woodline Partners LP raised its position in shares of Septerna by 94.2% in the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after buying an additional 282,585 shares during the last quarter. Rhumbline Advisers grew its stake in Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after acquiring an additional 3,323 shares in the last quarter. Geode Capital Management LLC grew its stake in Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after acquiring an additional 78,316 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Septerna in the 2nd quarter valued at about $129,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in Septerna by 116.7% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 222,702 shares of the company’s stock worth $2,354,000 after purchasing an additional 119,953 shares in the last quarter.

Insider Buying and Selling

In related news, COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total transaction of $115,880.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $5,046,834.73. The trade was a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the completion of the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $22,283.30. This represents a 98.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.30% of the stock is owned by corporate insiders.

Septerna News Roundup

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $40.00 price target on SEPN, signaling continued analyst conviction in the company’s longer‑term upside despite the cuts. MarketBeat SEPN page
• Neutral Sentiment: Coverage roundup: a Globe and Mail piece highlights mixed analyst views on several tech names including Septerna, underscoring market disagreement about timing and magnitude of recovery. Analysts Conflicted on These Technology Names
• Neutral Sentiment: HC Wainwright published multi‑quarter 2027 EPS projections (Q1–Q4 2027 and FY2027), providing a forward framework for the next fiscal year but not materially changing the firm’s Buy stance. MarketBeat SEPN page
• Negative Sentiment: HC Wainwright cut Q1–Q4 2026 quarter estimates (Q1 to ($0.46), Q2 to ($0.55), Q3 to ($0.62), Q4 to ($0.70)), lowering FY2026 EPS to ($2.34) from ($1.67). The downward revisions widen expected near‑term losses and create pressure on sentiment. MarketBeat SEPN page

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.